Stockscreener 앱 받기
150.06
2.56%
3.74
시장 영업 전:
146.06
-4.00
-2.67%
Ligand Pharmaceuticals Inc 주식(LGND)의 최신 뉴스
Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030 - Stock Titan
Ligand's Q2 2025: Unraveling Contradictions in Pelthos Launch, Deal Strategies, and Market Dynamics - AInvest
Will Ligand Pharmaceuticals Incorporated Recover After Recent DeclineStable Entry High Return Opportunities in Focus - beatles.ru
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q2 2025 Earnings Call Transcript - Insider Monkey
Ligand: RBC Raises PT to $185, Maintains Outperform Rating - AInvest
Ligand Pharma stock price target raised to $185 from $155 at RBC Capital - Investing.com Canada
Ligand Pharmaceuticals Among 3 Stocks Possibly Trading Below Intrinsic Value Estimates - Yahoo Finance
Ligand Pharmaceuticals Q2 2025 Earnings Call Highlights: Robust Royalty Growth and Strategic Partnerships - AInvest
Ligand Pharmaceuticals Raises FY25 EPS and Revenue Outlook, Boosts EPS View to $6.70-$7.00 and Revenue View to $200M-$225M. - AInvest
Ligand Pharmaceuticals Reports Q2 EPS and Revenue Above Consensus, Raises 2025 Guidance - AInvest
Ligand Pharmaceuticals Inc (LGND) Q2 2025 Earnings Call Highlights: Robust Royalty Growth and ... By GuruFocus - Investing.com Canada
Ligand Pharmaceuticals Reports Strong Q2 2025 Results - TipRanks
Ligand Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Ligand Pharmaceuticals Raises 2025 Revenue Guidance to $225M Amid Royalty Portfolio Momentum - AInvest
Transcript : Ligand Pharmaceuticals Incorporated, Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Ligand Pharma stock price target raised to $167 by Oppenheimer on strong royalty growth - Investing.com Canada
Earnings call transcript: Ligand Pharmaceuticals Q2 2025 beats forecasts, stock rises - Investing.com Canada
Ligand Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Ligand: Q2 Earnings Snapshot - San Francisco Chronicle
Ligand Q2 2025 presentation: 57% royalty growth drives raised guidance By Investing.com - Investing.com Canada
Ligand Pharmaceuticals Q2 2025 Earnings: Revenue Surpasses Estimates at $47.6M, EPS Falls Short at $0.24 - GuruFocus
Ligand Pharmaceuticals Reports 57% Increase in Royalty Revenue and Raises 2025 Financial Guidance - Quiver Quantitative
Ligand Pharmaceuticals Q2 revenue up 15%, raises 2025 guidance - MarketScreener
Ligand Q2 revenue up 57% YoY, FY23 guidance raised to $200-$225 mln. - AInvest
Ligand Pharmaceuticals Reports Q2 2025 Financial Results - TradingView
Press Release: Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance - 富途牛牛
Investors in Ligand Pharmaceuticals (NASDAQ:LGND) Have Seen Notable Returns of 36% Over the Past Year - 富途牛牛
Ligand Pharmaceuticals stock hits 52-week high at 143.31 USD By Investing.com - Investing.com Nigeria
Ligand Pharmaceuticals stock hits 52-week high at 143.31 USD - Investing.com
Ligand LGND 2025Q2 Earnings Preview Upside Ahead on Robust Revenue Growth - AInvest
Ligand Pharmaceuticals Incorporated Sees Relief Buying After Extended DropReal Trader Watchlist of Hot Stocks Released - metal.it
Price Channel Expanding on Ligand Pharmaceuticals Incorporated’s ChartReal Time Trade Opportunity Alerts Monitor Market Surges - metal.it
What is the risk reward ratio of investing in Ligand Pharmaceuticals Incorporated stockHigh-yield investments - Jammu Links News
How does Ligand Pharmaceuticals Incorporated compare to its industry peersDiscover undervalued opportunities early - Jammu Links News
Why is Ligand Pharmaceuticals Incorporated stock attracting strong analyst attentionAchieve rapid financial growth with smart picks - Jammu Links News
What makes Ligand Pharmaceuticals Incorporated stock price move sharplyFastest return on investment - Jammu Links News
Is Ligand Pharmaceuticals Incorporated a good long term investmentCapitalize on momentum-driven opportunities - Jammu Links News
Ligand Pharmaceuticals to meet with Oppenheimer on July 28-29 - AInvest
Ligand Pharmaceuticals Incorporated to Host Earnings Call - ACCESS Newswire
Orchestra BioMed secures $70 million from Ligand and Medtronic By Investing.com - Investing.com South Africa
Orchestra BioMed secures $70 million from Ligand and Medtronic - Investing.com
Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed - GlobeNewswire
$70M Strategic Investment Powers Orchestra BioMed's Revolutionary Leadless Pacemaker Technology - Stock Titan
How Ligand Pharmaceuticals Incorporated stock performs during market volatilityTrend Analysis for Safer Trades Gains Popularity - beatles.ru
When is Ligand Pharmaceuticals Incorporated stock expected to show significant growthSmart Portfolio Planner With Proven Results - Jammu Links News
LGND: Oppenheimer Raises Price Target for Ligand Pharmaceuticals - GuruFocus
Ligand Pharmaceuticals Price Target Raised Amid Positive Developments - AInvest
Oppenheimer Raises Ligand Pharmaceuticals PT to $162 from $145 to Outperform. - AInvest
Oppenheimer raises Ligand Pharma stock price target to $162 on royalty growth - Investing.com Australia
Oppenheimer raises Ligand Pharma stock price target to $162 on royalty growth By Investing.com - Investing.com South Africa
Key External Factors That Drive Ligand Pharmaceuticals Incorporated Stock Price MovementsLow Risk Equity Screener With Results Shared - metal.it
Ligand Pharmaceuticals Incorporated Recovery Likely Here’s What Data ShowsAI Powered High Return Stock Calls Dominate Watchlists - metal.it
Published on: 2025-07-29 17:16:20 - metal.it
EQUITY NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm - ACCESS Newswire
Why Ligand Pharmaceuticals Incorporated stock attracts strong analyst attentionDaily Stock Market Swing Alerts Highlight Key Movers - metal.it
Published on: 2025-07-29 03:23:14 - metal.it
What are Ligand Pharmaceuticals Incorporated company’s key revenue driversUnprecedented profits - jammulinksnews.com
RSI Crosses Above 30 for Ligand Pharmaceuticals Incorporated — Reversal in SightAI Based High Gain Watchlist Scanner Shared - beatles.ru
Is Ligand Pharmaceuticals Incorporated stock overvalued or undervaluedHigh-performance investment picks - Jammu Links News
0.24%
3.39%
자본화:
|
볼륨(24시간):